

IMPORTANT INFORMATION CONCERNING THE RIGHTS ISSUE APRIL

THE INFORMATION MAY NOT BE DISCLOSED, PUBLISHED, OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA SINGAPORE, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW.

The information contained herein may not be disclosed, published, or distributed, directly or indirectly, within or to the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such action would be illegal, subject to legal restrictions or require measures other than those that follow from Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation, and does not constitute an offer to sell, or a solicitation of an offer to purchase, any shares or other securities of Disruptive Pharma Holding AB (publ) (the "Company") in any of the above-mentioned jurisdictions or in any other jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.

No shares, subscription rights, paid subscription shares or other securities issued by the Company have been registered, and no shares, warrants, or other securities will be registered, under the United States Securities Act of 1933 (the "Securities Act") or the securities laws of any state or other jurisdiction from time to time. In the United States and may not be offered, sold, or otherwise transferred, directly or indirectly, in or to the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and pursuant to securities laws in the relevant state or other jurisdiction of the United States. The Securities have not been and will not be approved or registered by the Securities and Exchange Commission, any state securities authority or other authority in the USA. No such authority has assessed or made any statements about the Rights Issue or the accuracy or reliability of the prospectus. To assert the contrary is a criminal act in the USA.

For persons in member states of the European Economic Area (each a "Relevant State") (excluding Sweden), the materials you are seeking to access are only addressed to, and directed at, persons who are "qualified investors" within the meaning of Article 2(e) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation") ("Qualified Investors"). In any Relevant State, the materials you are seeking to access are directed only at Qualified Investors and must not be acted on or relied on by persons who are not Qualified Investors. Any investment or investment activity to which these materials relate is available in any Relevant State only to Qualified Investors and will be engaged in only with such persons.

For persons in the United Kingdom, the materials you are seeking to access are only addressed to, and directed at, persons who are "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation, as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018, who: (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"); (ii) fall within Article 49(2)(a) to (d) of the Order; or (iii) are otherwise persons to whom it may otherwise lawfully be communicated (all such persons being referred to as "Relevant Persons"). In the United Kingdom, the materials you are seeking to access are directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which these materials relate is available in the United Kingdom only to Relevant Persons, and will be engaged in only with such persons.

Access to the information and documents contained on the following website may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such information and documents. All persons residing outside of Sweden who wish to have access to the information and documents contained on this website should firstly ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website or require registration or approval of any acquisition of securities by them. No such registration or approval has been obtained outside Sweden. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.

Access to electronic versions of these materials is being made available on this website by the Company in good faith and for information purposes only.

By accessing the information and documents on this part of the Company's website, I therefore certify that:

I am resident and physically present outside the United States, Canada, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or Switzerland or any other jurisdiction in

which the release, distribution or publication would be unlawful or require registration or any other measure in accordance with applicable law; or

I am resident and physically present (a) in Sweden or (b) outside Sweden and each of the jurisdictions referred to in clause (1) above and, in that case, I am authorized to access the information and documents on this website without being subject to any legal restriction and without any further action required by the Company.

I have read, understand and agree to comply with all of the restrictions set forth above.